Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liprotamase versus Pancreaze in cystic fibrosis-related exocrine pancreatic insufficiency
2015-002739-17Phase 3Completed
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Oct 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of liprotamase in cystic fibrosis (CF) (2 arms), sponsored by Anthera Pharmaceuticals, Inc. Primary endpoint: Change in coefficient of fat absorption. Started Oct 2015; status: completed.
02
Drugs
liprotamase
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-002739-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002739-17.